Qapzola (apaziquone) / Assertio - LARVOL DELTA

Ultimate and primary biodegradation of a range of non-polymeric and polymeric surfactants in seawater. (PubMed, Environ Toxicol Chem) - "A primary biodegradation experiments of the alcohol ethoxylate (AE) C12-EO9 (3 to 18 EO groups) in a carousel system at 20°C with natural SW and a surfactant concentration of 500 µg/L, showed rapid primary biodegradation by targeted analyses of the AE, with >99% primary biodegradation after 2 days of incubation...Environ Toxicol Chem 2023;00:0-0."

Journal • Multiple Sclerosis

Development of Hif1a Pharmacogenomic Mutation Models to Study Individual Variations in Drug Action for Tumor Hypoxia: An in Silico Approach. (PubMed, J Pharm Bioallied Sci) - "Potential models were used for interaction studies with hypoxia-specific molecules (tirapazamine, apaziquone, and ENMD) using docking analysis. It also elucidates that the therapeutic effect is altered concerning population-dependent genetic changes in the individual. The study, therefore, asserts the need to set up a personalized drug design approach to enhance tumor hypoxia treatment efficacy."

Biomarker • Journal • Oncology • Solid Tumor • HIF1A

Review on NAD(P)H dehydrogenase quinone 1 (NQO1) pathway. (PubMed, Mol Biol Rep) - "The quinone derivative compounds like mitomycin C, RH1, E09 (Apaziquone) and β-lapachone causes cell death by NQO1 reduction of two electrons. The NQO1 exhibit suppression of chemical-mediated carcinogenesis by various properties of NQO1 which includes, detoxification of quinone scavenger of superoxide anion radical, antioxidant enzyme, protein stabilizer. This review outlines the NQO1 structure, mechanism of action to inhibit the cancer cell, functions of NQO1 against oxidative stress, drugs acting on NQO1 pathways, clinical significance."

Journal • Review • Oncology • NQO1

A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) (clinicaltrials.gov) - P3; N=118; Terminated; Sponsor: Spectrum Pharmaceuticals, Inc; N=500 ➔ 118; Active, not recruiting ➔ Terminated; Suspended development

Clinical • Enrollment change • Trial termination • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy. (PubMed, Front Oncol) - "Both single-agent and combined use with other drugs have shown promising antitumor effects. In this review, we discuss the mechanism of action and the current preclinical and clinical progress of several of the most widely used HAPs, summarize their existing problems and shortcomings, and discuss future research prospects."

Review • Oncology • Solid Tumor

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT (clinicaltrials.gov) - P3; N=62; Terminated; Sponsor: Spectrum Pharmaceuticals, Inc; N=1869 ➔ 62; Active, not recruiting ➔ Terminated

Clinical • Enrollment change • Trial termination • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Patients Undergoing TURBT (clinicaltrials.gov) - P3; N=500; Active, not recruiting; Sponsor: Spectrum Pharmaceuticals, Inc; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed